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Introduction

DNA. 116
The pEGFPN1 and mCherry plasmids were obtained from Addgene (Addgene, USA). The 117 plasmid encoding for HA-tagged ubiquitin was a kind gift from Soham Gupta (Karolinska 118 Institutet, Sweden). pCR3.1/HIV-gag-mCherry (HIV-1B gag ) and pCR3.1-GFP-ALIX plasmids 119 were kind gifts from Dr. Paul Bieniasz (The Rockefeller University, USA). A codon-optimized 120
HIV-1 gag with PYQE motif gene of East African HIV-1C viruses was cloned into the 121 pCR3.1/HIV-gag-mCherry plasmid that contained a mCherry protein C-terminal tag sequence. 122
The gag-PYQE-mCherry plasmid was modified by site directed mutagenesis to make a base pair 123 substitution mutation (C to A) that changes the PYQE motif to PYKE using the Q5 SDM kit 124 (New England Biolabs, USA). Gag-PYQE-mCherry plasmid was linearized by PCR using 5'-125 AAGGAGCCTCTGACGAGCC-3' as forward primer (with the C to A base pair substitution 126 underlined) and 5'-ATAGGGACCCTGGTCTTTCAGC-3' as reverse primer. Linear products 127 were re-circularized using DpnI, a polynucleotide kinase and a ligase from the SDM kit following 128 the manufacturer's protocol. DNA sequences were verified by Sanger sequencing. 129
Gag-p6 sequences and clinical specimens 130
In silico analysis: Molecular modelling, docking and Ubiquitin binding motif prediction 146
The structure of HIV-1C gag late domain with the PYKE insertion was generated by homology 147 modeling techniques. The crystal structures of the gag late domain in complex with ALIX (PDB 148 entries 2XS1 and 2R02) were used as template molecules. For this purpose, the 'Prime' utility of 149 Schrödinger Suite (Schrödinger Inc., USA) was used. The structure was subjected to restricted 150 minimization using OPLS_2005 force field. This structure was docked into the crystal structure 151 of ALIX (PDB file 2XS1) using protein-protein docking program of 'BioLuminate' (Schrödinger 152 Inc., USA), after deleting SIV mac239 PYKEVTEDL late domain structure. The resulting structure 153 was further minimized for 1000 iterations to remove steric clashes. A similar protocol was used 154 to form the complex among ALIX, gag late domain and ubiquitin. The crystal structure of 155 ubiquitin in complex with the TSG101-binding PTAP domain (PDB file 1S1Q) was used after 156 exclusion of TSG101 coordinates. The entire complex was then subjected to molecular dynamics 157 simulations for 1,000,000 steps with step size of 50 pico seconds using OPLS3 force field. The 158 most energetically stable model of the complex was used for further analysis. In order to obtain 159 energetically favoured polar interactions, the conformational search of polar sidechains at the 160 interface of proteins was also conducted. 161
The prediction of ubiquitin binding with the HIV-1C gag late domain with the PYKE motif P6 162 was performed by adding the amino acid sequence in the prediction tools presented at the website 163 http://www.ubpred.org/. 164
Immunofluorescence 165
HEK293T cells were cultured on poly-L-lysine-coated glass coverslips and co-transfected with 166 GFP-tagged ALIX and mCherry-tagged codon-optimized gag variants. At 24 hours post 167 transfection, cells were washed twice with PBS, fixed in 10% formalin (Sigma, USA) for 20 min 168 at room temperature, washed three times with PBS, and stored in PBS at 4°C. Later, nuclear 169 counterstaining with DAPI was performed followed by mounting of the glass coverslips on glass 170 slides. When HA-ubiquitin was also co-transfected, cells were fixed in ice-cold methanol for 15
The microscale thermophoresis experiments were conducted by Monolith NT0.115 instrument 180 (NanoTemper Technologies) at 40% MST and LED power at 25°C. Hexahistidine-tagged ALIX 181 protein was labelled by NTA-dye (NanoTemper Technologies) using manufacturer's protocol. 182
The peptides were synthesized at the Molecular Interaction Core (University of Missouri). 183
Thermophoresis was induced by mixing peptides (0.001-1µM) and fixed NTA-labelled ALIX (50 184 nM) in a buffer 50 mM Tris-Cl pH 7.8, 100 mM NaCl and 0.1% pluronic-F127. The binding 185 isotherms were obtained by plotting the difference in normalized fluorescence against increasing 186 peptide concentration. The binding affinities were determined fitting the data points to a 187 quadratic equation ( 
Co-immunoprecipitation assay 195
HEK293T cells were co-transfected with GFP-tagged ALIX and codon-optimized gag variants 196 from HIV-1B or HIV-1C. At 24 hours post transfection, cells were collected, washed twice with 197 ice-cold PBS and immunoprecipitation of GFP-tagged proteins was performed using Trap®_A kit (Chromotek, Germany) according to manufacturer's protocol. Briefly, cells were 199 lysed in ice-cold lysis buffer (10 mM Tris pH 7.5, 150 mM NaCl, 0.5 mM EDTA, 0.5% 200 supplemented with a protease cocktail inhibitor from Roche, Switzerland) for 30 minutes on ice. 201
Then lysates were diluted in ice-cold wash buffer (10 mM Tris pH 7.5, 150 mM NaCl, 0.5 mM incubated with equilibrated GFP-Trap®_A beads end-over-end for 1 hour at 4°C. Beads were 205 washed three times with ice-cold wash buffer before resuspending in 2x Leammli buffer 206 (Invitrogen, 4x buffer diluted 1:1 with PBS) and heated for 10 minutes at 95°C. Protein 207 concentration of input samples was determined by DC protein assay (Biorad, USA) according to 208 the manufacturer's microplate assay protocol. Equal amounts of protein for input samples and 209 equal volumes of pull-down samples were subjected to immunoblotting using primary antibodies 210 against GFP (rabbit monoclonal, clone EPR14104, Abcam, UK), gag (rabbit polyclonal to HIV1 211 p55 + p24 + p17, Abcam, ab63917), and β-actin (rabbit polyclonal, Abcam, ab8227) and 212 secondary horseradish peroxidase-conjugated antibodies (polyclonal goat anti-rabbit, 213 DAKO/Agilent, USA). Immunoblotted proteins were detected using the enhanced 214 analysis to these two variants. 280
In silico analysis predicts binding of ALIX to the PYKE motif in gag 281
As reported before, the lysine residues in the gag-p6 are subjected to ubiquination (21), we first 282 predicted the likelihood of K ins ubiquitination compared to lysine residues adjacent to the PYKE 283 motif. Indeed, K ins was predicted to be more likely ubiquitinated than lysine residues in the 284 vicinity of the PYKE motif ( Fig.2a ). Since the PYKE motif is present at the missing ALIX-285 binding site and contains three charged amino acids that can facilitate interaction with other 286 proteins, we used the PYKE insertion (amino acids 483 to 486) in the molecular modelling to 287 predict the interaction of the gag-p6 late domain with ALIX. Amino acids E482, Y484 and E486 288 of gag could directly facilitate binding to ALIX ( Fig.2b and Table 1 ). Ubiquitin was predicted to 289 bind K501 in ALIX and thereby affect the interaction between E486 in gag-PYKE with K501 in 290 ALIX. In addition, ubiquitin could also interact with E387 of ALIX and K ins of gag-PYKE both proteins. 293T cells were co-transfected with GFP-tagged ALIX with or without three 298 codon-optimized variants of mCherry-tagged HIV-1C gag, namely wild type gag or gag that 299 includes the tetrapeptide insertion PYKE or PYQE. Confocal analysis showed cytoplasmic 300 localization of ALIX and predominant plasma membrane localization of all three gag variants 301 (HIV-1C wildtype , HIV-1C PYQEi and HIV-1C PYKEi ) ( Fig.3a) . We also tested the localization of 302 ubiquitin in this context. Since both gag and ALIX are known to be ubiquitinated, it is not 303 surprising that ubiquitin co-localized with ALIX and gag (Fig.3b) . Thus, the localization of gag 304 was not due to the tetrapeptide insertion, but most likely due to PTAP:TSG101-facilitated 305 transport of gag to and viral budding from the plasma membrane. 306
Next, we evaluated the binding affinity of the four HIV-1C gag variants, HIV-1B WT (Fig 4a) , 307
HIV-1C WT (Fig 4b) , HIV-1C PYKEi (Fig 4c) and HIV-1C PYQEi (Fig 4d) , to ALIX. The late domain 308 motifs' peptides were selected based on crystal structure PDB:2XS1 and PDB:2R02. The binding 309 affinity of the gag peptide with ALIX were statistically significantly higher in HIV-1B WT (32 ± 3 310 nM) compared to all HIV-1C variants, HIV-1C WT (290 ± 6 nM), HIV-1C PYKEi (110 ± 4 nM), 311
HIV-1C PYQEi (96 ± 4 nM) (Fig 4e) . However statistically significant higher binding affinity to 312 ALIX was observed with HIV-1C PYKEi and HIV-1C PYQEi compared to HIV-1C WT (Fig 4e) . 313
As the peptides may not retain their conformal structures as in the complete protein, we 314 confirmed the binding by co-immunoprecipitation pull-down assays. GFP-tagged ALIX and 315 HIV-1C gag variants were transfected either alone or together in 293T cells. A plasmid encoding 316 for HIV-1B gag was used together with GFP-ALIX as a positive control for gag:ALIX 317 interaction. Lysates were prepared 24h post-transfection, GFP-tagged proteins were pulled down 318 and co-immunoprecipitated proteins were analysed by immunoblotting (Fig.4b) . GFP-tagged 319 detected when co-transfected with GFP-ALIX, but HIV-1C gag PYKE was more prominently 322 detected. The intensity of HIV-1C gag PYQE was consistently lower than that of the PYKE 323 variant, but slightly increased compared to the wild type HIV-1C gag, indicating that potential 324 ubiquitination of the lysine residue is not a necessity, although it can facilitate a stronger 325 interaction of gag with ALIX. Thus, the tetrapeptide insertion PYxE in HIV-1C gag-p6 late 326 domain promotes binding of gag towards ALIX. 327
Differences in viral growth and drug responses of clinical strains of HIV-1C with PYxE motif 328
Finally, we assessed the consequence of the PYxE insertion on HIV-1C replication fitness using 329 clinical strains obtained from HIV-1C infected patients. Gag-pol sequences were cloned from one 330 wildtype HIV-1C virus with a single PTAP motif and no PYxE insertion (PT01), three HIV-1C 331 strains with a PYKE insertion (PT04-06), one with a PYQE insertion (PT07). We also included 332 two HIV-1C strains with a PTAP duplication (PT02 and PT03) as it has been shown to increase 333 the viral fitness and affect the drug sensitivity (Fig.5a ). Then, these sequences were cloned into 334 the genome of a reference virus (NL4-3, HIV-1B wild type) replacing its gag-pol sequence. The 335 various recombinant viruses were tested for viral replication in an ex vivo viral growth kinetic 336 assay and compared to the reference virus (Fig.5b) . In concordance with a previous report (22) PYxE has replication advantages, we hypothesize that these strains have evolved through a 373 recombination event of HIV-1C with either SIV or HIV-2. It is well described that the HIV-1 374 epidemic in Ethiopia geographically clusters very strongly (25) and the Ethiopian HIV-1C has 375 been proposed to originate from either a single lineage or multiple descendants (26). However to 376 explain why the PYxE insertion is significantly more prevalent in HIV-1C from Ethiopia and 377
Eritrea as compared to South African and Indian strains need further evolutionary study to prove 378 this hypothesis. 379 Viral budding is mediated by the gag-p6 late domain of gag through the PTAP motif, the YPx n L 380 motif, and the PYxE motif. The PTAP motif mediates binding of gag to ESCRT protein TSG101 381 and is present in all HIV and SIV variants. Therefore, this domain appears to be necessary for 382 viral budding. Although one report shows that PTAP duplication only increases HIV-1 383 replication in the presence of a PI (27), others and we observed increased viral growth when 384
HIV-1 contained a PTAP duplication (28). Although deletion of the PTAP motif has not been 385 identified in clinical strains so far, artificial deletion or mutation of this PTAP motif severely 386 abrogates release of HIV-1 from infected cells (11, 29, 30). However, the presence of either one 387 of the two other motifs that both facilitate binding to host cell protein ALIX still allows for virion 388 release (12, 14, 19, 31, 32) . This indicates that both TSG101-and ALIX-mediated pathways for viral budding are not dependent on each other and each pathway is sufficient to mediate viral 390 budding. The first ALIX-binding motif is YPx n L and is present in most HIV-1 subtypes but not in 391 HIV-1C or HIV-2 (13, 14). HIV-2 gag can mediate binding to ALIX through a distinct 392 PYKEVTEDL motif, and mutations in this motif can abrogate ALIX binding and decrease virion 393 release (14, 24). Thus, the PYxE motif in a subgroup of HIV-1C strains is similar but shorter than 394 the ALIX-binding motif found in HIV-2. We showed that this insertion of PYxE in HIV-1C gag 395 at the natural deletion site of the YPx n L domain could reconstitute binding of HIV-1C gag to 396 ALIX. Hence, together with our observed PYxE insertion in HIV-1C, all HIV-1 subtypes have an 397 ALIX-binding motif next to their PTAP-motif within the gag late domain. 398
Our data suggests that ubiquitin may play a role in facilitating the binding of ALIX to the PYKE 399 motif. This is not surprising, as ubiquitin has been shown to be involved in viral budding of HIV. 400
Although dispensable for virus budding, ubiquitination of gag and the ESCRT-proteins are 401 essential for efficient release of HIV-1 from infected cells (21, 33, 34). Ubiquitination of the 402 lysine of the PYKE motif could increase the binding between ALIX and gag and thereby mediate 403 more efficient viral budding. Indeed, immunoprecipitation of HIV-1C gag-PYKE was more 404 efficient compared to the gag-PYQE variant (Fig.4b) . As the PYKE motif insertion seems to be 405 the original insertion within HIV-1C gag, ubiquitination of its lysine might not be essential since 406 other variants of the PYKE motif, i.e. PYQE and PYRE, are identified among HIV-1C strains 407 along with evolution of other lysine (K) residues in the late domain. Because we only have few 408 clinical strains with a PYxE insertion, we could not identify differences in viral growth between 409 HIV-1C gag-PYKE and other PYxE variants (Fig.5) . Nonetheless, whereas the other three 410 residues seem to be required for the binding of ALIX to gag, the lysine residue might provide 411 increased stability for this interaction. 412
Although the ALIX-mediated viral budding mechanism appeared to be lost in HIV-1C, it is 413 surprising to observe that HIV-1C PYxE strains were prevalent among HIV-1C infected 414 individuals. This suggests that the interaction of gag with ALIX is of biological importance for 415 the virus. In our limited cohort of HIV-1C infected patients, PYxE insertion was always co-416 present with the PTAP motif. This suggests that the PYxE motif is not redundant from the PTAP 417 motif-mediated viral budding process through TSG101 nor a compensatory mechanism for loss 418 of the PTAP-motif and HIV-1 requires both motifs for efficient viral replication. Importantly, 419 viruses with HIV-1C gag PYKE or PYQE insertion showed enhanced viral growth compared to showed that a PYRE insertion within gag enhances HIV-1C viral growth (19) . 422
Decreased sensitivity towards PI LPV or NRTI TAF was found in several HIV-1C strains with a 423 PTAP duplication or PYxE insertion. For the PTAP duplication it has previously been reported 424 that it could enhance HIV-1 growth in the presence of PIs lopinavir and ritonavir (27) . For the 425 PYxE insertion, our earlier studies have shown that the PYxE insertion is more frequent in HIV-426 1C therapy-failure patients (15, 16) . Nonetheless, since our clinical HIV-1C PYxE strains did not 427 have any known drug resistance mutations, it seems likely that the correlation of these viruses 428 with advanced viral growth and reduced sensitivity towards the PI LPV and TAF could increase 429 the risk for therapy failure in HIV-1C PYxE-infected patients. Though mechanistic studies shows 430 that at the time of reverse transcription of HIV-1C from the RNA template, the nucleotide in 431 HIV-1C K65 position (AAG) in RT favoured pausing, which increases the probability for the 432 development of TDF/TAF mutation K65R (35, 36) . However no studies have shown any co-433 relation with gag-mutation on susceptibility of TAF. We are presently performing research to 434 understand the role of gag mutations on sensitivity for TAF as both tenofovir (TDF) and TAF are 435 used globally. 436
In conclusion, our study showed that PYxE insertion in HIV-1C of patients originating from 437
Ethiopia and Eritrea restored the interaction of gag with ALIX, which is mediated in an ubiquitin-438 dependent or -independent way. Importantly, the insertion was positively correlated with the 439 replication fitness that could affect the sensitivity against LPV in the absence of any PI drug 440 resistance mutation. Most importantly, reduced sensitivity against TAF in the absence of any 441 TAF-mutation needs further studies to analyse any role of gag-mutations in reducing 442 susceptibility towards TAF. Altogether, it will be important to follow up on whether HIV-1C PYxEi 443 strains are emerging following the failure of antiretroviral therapy with LPV and TAF based 444 regimens due to increased replication fitness. This information could provide important insights 445 in the clinical significance of the PYxE insertion within HIV-1C gag. 446 
